In keeping with these data, diabetes and cardiology guidelines and professional societies recommend a GLP-1 RA with demonstrated cardiovascular benefit for the treatment of individuals with T2D and established or at high risk for ASCVD. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.